Important Announcement

X

ChemIDplus is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Disopyramide phosphate [USAN:USP:BAN:JAN]
RN: 22059-60-5
UNII: N6BOM1935W
InChIKey: CGDDQFMPGMYYQP-UHFFFAOYSA-N

Note

  • A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

Molecular Formulas

  • C21-H29-N3-O.H3-O4-P
  • C21-H29-N3-O.H3-P-O4

Molecular Weight

  • 437.4738
 

Classification Codes

  • Cardiac Depressant (Anti-Arrhythmic)
  • Drug / Therapeutic Agent
  • Human Data
  • Reproductive Effect
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Disopyramide phosphate [USAN:USP:BAN:JAN]

Synonyms

  • (+-)-alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
  • 2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (+-)-, phosphate (1:1)
  • alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
  • alpha-(2-Diisopropylaminoethyl)-alpha-phenyl-2-pyridineacetamide phosphate
  • Disopyramide phosphate
  • EINECS 244-756-1
  • Norpace
  • Norpace CR
  • NSC 756744
  • Rythmodan
  • SC 13957
  • SC 7031 phosphate
  • SC-13957
  • UNII-N6BOM1935W

Systematic Names

  • 2-(1-(Ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium phosphate
  • 2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate
  • 2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate (1:1)
  • 2-Pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-, phosphate

Registry Numbers

CAS Registry Number

  • 22059-60-5

FDA UNII

  • N6BOM1935W

Related Registry Number

  • 3737-09-5 (Parent)

System Generated Number

  • 0022059605

Molecular Formulas

Molecular Formulas

  • C21-H29-N3-O.H3-O4-P
  • C21-H29-N3-O.H3-P-O4

Molecular Formula Fragments

  • C21-H29-N3-O
  • COMPONENT
  • H3-O4-P
  • H3-P-O4

Structure Descriptors

InChI

InChI=1S/C21H29N3O.H3O4P/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;1-5(2,3)4/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);(H3,1,2,3,4)

InChIKey

CGDDQFMPGMYYQP-UHFFFAOYSA-N

Smiles

CC(C)N(CCC(C(=O)N)(c1ccccc1)c2ccccn2)C(C)C.OP(=O)(O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child LDLo oral 30mg/kg (30mg/kg) KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Medical Journal of Australia. Vol. 2, Pg. 335, 1978.
dog LDLo intravenous 30mg/kg (30mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 6, Pg. 147, 1980.
man LDLo oral 214mg/kg (214mg/kg)   Journal of Analytical Toxicology. Vol. 6, Pg. 255, 1982.
man TDLo oral 1429ug/kg (1.429mg/kg) ENDOCRINE: HYPOGLYCEMIA Nippon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine. Vol. 72, Pg. 1177, 1983.
man TDLo oral 43mg/kg/5D-I (43mg/kg) ENDOCRINE: HYPOGLYCEMIA New York State Journal of Medicine. Vol. 83, Pg. 1057, 1983.
man TDLo oral 45mg/kg/1W-I (45mg/kg) BEHAVIORAL: COMA Southern Medical Journal. Vol. 76, Pg. 1453, 1983.
man TDLo oral 286mg/kg (286mg/kg) LUNGS, THORAX, OR RESPIRATION: CYANOSIS

CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
Postgraduate Medical Journal. Vol. 56, Pg. 256, 1980.
mouse LD50 intraperitoneal 190mg/kg (190mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9(Suppl,
mouse LD50 intravenous 81mg/kg (81mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9(Suppl,
mouse LD50 oral 820mg/kg (820mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9(Suppl,
mouse LD50 subcutaneous 680mg/kg (680mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9(Suppl,
rat LD50 intraperitoneal 255mg/kg (255mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9(Suppl,
rat LD50 intravenous 41mg/kg (41mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 7, Pg. 133, 1981.
rat LD50 oral 880mg/kg (880mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9(Suppl,
rat LD50 subcutaneous 1gm/kg (1000mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9(Suppl,
women LDLo oral 60mg/kg/10D-I (60mg/kg) ENDOCRINE: HYPOGLYCEMIA New York State Journal of Medicine. Vol. 83, Pg. 1057, 1983.
women LDLo oral 75mg/kg (75mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Journal of the Irish Medical Association. Vol. 71, Pg. 552, 1978.
women TDLo oral 8mg/kg/1D-I (8mg/kg) BLOOD: CHANGE IN CLOTTING FACTORS

LIVER: LIVER FUNCTION TESTS IMPAIRED

BLOOD: THROMBOCYTOPENIA
Southern Medical Journal. Vol. 75, Pg. 496, 1982.
women TDLo oral 20mg/kg/3D-I (20mg/kg) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)
American Heart Journal. Vol. 105, Pg. 870, 1983.